<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892099</url>
  </required_header>
  <id_info>
    <org_study_id>2009P-000398</org_study_id>
    <secondary_id>R01DK084974</secondary_id>
    <nct_id>NCT00892099</nct_id>
  </id_info>
  <brief_title>DIVINE: Dialysis Infection and Vitamin D In New England</brief_title>
  <official_title>DIVINE: Dialysis Infection and Vitamin D In New England</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection is the second-leading cause of death in individuals requiring dialysis treatment
      for kidney failure. New research suggests the high risk of infection may be due in part to
      low levels of vitamin D, which are extremely common in kidney disease. This study is designed
      to determine safe and effective ways to raise vitamin D levels while monitoring effects on
      the immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that a profound deficiency of nutritional vitamin D (25-hydroxyvitamin D, 25D)
      in end-stage renal disease (ESRD) leads to an altered immune response, predisposing to early
      morbidity and mortality from infection, the second-leading cause of death in ESRD. In
      addition to impaired renal synthesis of the hormonal form of vitamin D (1,25-dihydroxyvitamin
      D; 1,25D), ESRD is accompanied by near universal insufficiency of 25D. In-vitro, ex-vivo, and
      retrospective human studies by our group and others suggest that 25D (and not 1,25D) is
      intimately linked to immune defense via alterations in the production of inflammatory
      cytokines and critical antimicrobial peptides including cathelicidin, which we have shown to
      identify ESRD subjects at risk for infection-related mortality. Ergocalciferol, which is
      rapidly converted to 25D, is the most widely available form of nutritional vitamin D in the
      US, yet guidelines to treat ESRD patients with nutritional vitamin D are absent because of
      limited data supporting its efficacy, safety, and biological effects in this population. To
      determine effective and safe doses of ergocalciferol in ESRD, we will perform a double blind
      placebo controlled randomized trial in 120 incident hemodialysis patients (40/arm x 3) with
      25D levels &lt; 30ng/ml, comparing two ergocalciferol dosing regimens (50,000 IU/week and 50,000
      IU/month) and an identically appearing placebo. The primary outcome will be correction of
      vitamin D insufficiency (25D &gt;30 ng/ml) at 12 weeks. Serum calcium and phosphate levels will
      be measured every 4 weeks to assess safety, and blood cytokine and cathelicidin levels will
      be measured every 4 weeks to determine biological responses. To examine biological effects in
      greater detail, a subset of subjects from each arm of the study will be further analyzed with
      serial macrophage gene expression profiles and whole blood cytokine profiles following
      ex-vivo stimulation with pro-inflammatory mediators (e.g., killed S. aureus). These
      experiments will inform us on how individuals with ESRD, based on their vitamin D status and
      the treatment they receive, may respond to infection. Laboratory measures will continue for
      12 weeks. Clinical follow-up and monitoring for infection-associated events (including
      antibiotic use, rates of bacteremia, and sepsis) will continue for 20 weeks. This pilot trial
      addressing a significant unmet need in nephrology will involve basic, translational, and
      clinical investigators experienced in vitamin D research, infection and inflammation, and in
      trials involving ESRD subjects. These data will provide an important foundation for designing
      future clinical trials rigorously assessing the effect of nutritional vitamin D on infectious
      and other outcomes in ESRD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25D Level</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>every 4 weeks for 12 weeks</time_frame>
    <description>serum calcium levels (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Phosphate</measure>
    <time_frame>every 4 weeks for 12 weeks</time_frame>
    <description>serum phosphate levels (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 25-OH Vitamin D</measure>
    <time_frame>every 4 weeks for 12 weeks</time_frame>
    <description>serum 25-OH vitamin D levels (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 1,25(OH)2 Levels</measure>
    <time_frame>At week 12</time_frame>
    <description>serum 1,25(OH) vitamin D levels (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathyroid Hormone</measure>
    <time_frame>every 4 weeks for 12 weeks</time_frame>
    <description>serum PTH levels (pg/mL)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>High Dose Ergocalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives 50,000 IU of ergocalciferol weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Ergocalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives 50,000 IU of ergocalciferol per month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receives no ergocalciferol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>50,000 IU tablet given weekly</description>
    <arm_group_label>High Dose Ergocalciferol</arm_group_label>
    <other_name>vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>50,000 IU tablet given monthly</description>
    <arm_group_label>Low Dose Ergocalciferol</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age â‰¥ 18 years

          -  Initiating chronic hemodialysis 3x/wk at Massachusetts General Hospital, Brigham and
             Women's Hospital or Beth Israel Deaconess Medical Center with planned transfer to
             Massachusetts chronic facility

          -  Serum 25D &lt; 32 ng/ml

          -  Corrected serum calcium &lt; 10.2 mg/dl

          -  Serum phosphate &lt; 5.5 mg/dl

          -  Serum albumin &gt; 3 g/dL

          -  Informed consent

        Exclusion Criteria

          -  Pregnant or breastfeeding

          -  Women of childbearing potential not practicing one of the following measures of birth
             control: double-barrier method, hormonal contraceptives for at least 3 months prior to
             and during study, monogamous relationship with vasectomized partner, total abstinence
             from sexual intercourse with men during study.

          -  HIV positive

          -  History of allergic reaction to ergocalciferol

          -  Investigator considers subject unsuitable for any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Thadhani, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bhan I, Camargo CA Jr, Wenger J, Ricciardi C, Ye J, Borregaard N, Thadhani R. Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. J Allergy Clin Immunol. 2011 May;127(5):1302-4.e1. doi: 10.1016/j.jaci.2010.12.1097. Epub 2011 Feb 9.</citation>
    <PMID>21310475</PMID>
  </reference>
  <results_reference>
    <citation>Ishir Bhan, Dorothy A Dobens, Caitlin A. Trottier, Julia Beth Wenger, Hector Tamez, Joseph James Deferio, Kathryn J. Lucchesi, Ravi I. Thadhani. The DIVINE Trial: Dialysis Infection and Vitamin D in New England J. Am. Soc. Nephrol 24:2013 (Abstract: SA-PO1082)</citation>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>May 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <results_first_submitted>May 22, 2015</results_first_submitted>
  <results_first_submitted_qc>May 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2015</results_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ravi Thadhani</investigator_full_name>
    <investigator_title>Director of Clinical Research in Nephrology</investigator_title>
  </responsible_party>
  <keyword>end stage renal disease</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>replocated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prolonged hospitalization</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no further details</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>kidney function recovered</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="17"/>
                    <measurement group_id="B2" value="58" spread="16"/>
                    <measurement group_id="B3" value="59" spread="17"/>
                    <measurement group_id="B4" value="57" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25(OH) vitamin D</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.8" spread="7"/>
                    <measurement group_id="B2" value="22.3" spread="6.5"/>
                    <measurement group_id="B3" value="21.7" spread="7.3"/>
                    <measurement group_id="B4" value="21.9" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum 25D Level</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Serum 25D Level</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" spread="2.3"/>
                    <measurement group_id="O2" value="38.3" spread="2.4"/>
                    <measurement group_id="O3" value="27.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Calcium</title>
        <description>serum calcium levels (mg/dL)</description>
        <time_frame>every 4 weeks for 12 weeks</time_frame>
        <population>Subject receiving treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Calcium</title>
          <description>serum calcium levels (mg/dL)</description>
          <population>Subject receiving treatment</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="0.1"/>
                    <measurement group_id="O2" value="8.7" spread="0.1"/>
                    <measurement group_id="O3" value="8.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="0.1"/>
                    <measurement group_id="O2" value="8.9" spread="0.1"/>
                    <measurement group_id="O3" value="9.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="0.1"/>
                    <measurement group_id="O2" value="9.1" spread="0.1"/>
                    <measurement group_id="O3" value="9.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="0.1"/>
                    <measurement group_id="O2" value="9.1" spread="0.1"/>
                    <measurement group_id="O3" value="9.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Phosphate</title>
        <description>serum phosphate levels (mmol/L)</description>
        <time_frame>every 4 weeks for 12 weeks</time_frame>
        <population>Subject receiving treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Phosphate</title>
          <description>serum phosphate levels (mmol/L)</description>
          <population>Subject receiving treatment</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.2"/>
                    <measurement group_id="O2" value="4.2" spread="0.2"/>
                    <measurement group_id="O3" value="4.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.3"/>
                    <measurement group_id="O2" value="4.7" spread="0.3"/>
                    <measurement group_id="O3" value="4.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.3"/>
                    <measurement group_id="O2" value="5.2" spread="0.3"/>
                    <measurement group_id="O3" value="5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.3"/>
                    <measurement group_id="O2" value="5.4" spread="0.3"/>
                    <measurement group_id="O3" value="4.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum 25-OH Vitamin D</title>
        <description>serum 25-OH vitamin D levels (ng/mL)</description>
        <time_frame>every 4 weeks for 12 weeks</time_frame>
        <population>Subject receiving treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Serum 25-OH Vitamin D</title>
          <description>serum 25-OH vitamin D levels (ng/mL)</description>
          <population>Subject receiving treatment</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="1.2"/>
                    <measurement group_id="O2" value="21.7" spread="1.2"/>
                    <measurement group_id="O3" value="22.3" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" spread="2.0"/>
                    <measurement group_id="O2" value="33.6" spread="2"/>
                    <measurement group_id="O3" value="27.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="2.2"/>
                    <measurement group_id="O2" value="35.6" spread="2.2"/>
                    <measurement group_id="O3" value="27" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" spread="2.3"/>
                    <measurement group_id="O2" value="38.3" spread="2.4"/>
                    <measurement group_id="O3" value="27.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum 1,25(OH)2 Levels</title>
        <description>serum 1,25(OH) vitamin D levels (pg/mL)</description>
        <time_frame>At week 12</time_frame>
        <population>Subject receiving treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Serum 1,25(OH)2 Levels</title>
          <description>serum 1,25(OH) vitamin D levels (pg/mL)</description>
          <population>Subject receiving treatment</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="66" upper_limit="135"/>
                    <measurement group_id="O2" value="100" lower_limit="68" upper_limit="140"/>
                    <measurement group_id="O3" value="120" lower_limit="62" upper_limit="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parathyroid Hormone</title>
        <description>serum PTH levels (pg/mL)</description>
        <time_frame>every 4 weeks for 12 weeks</time_frame>
        <population>Subject receiving treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone</title>
          <description>serum PTH levels (pg/mL)</description>
          <population>Subject receiving treatment</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281" spread="1"/>
                    <measurement group_id="O2" value="214" spread="1"/>
                    <measurement group_id="O3" value="243" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253" spread="1"/>
                    <measurement group_id="O2" value="195" spread="1"/>
                    <measurement group_id="O3" value="243" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" spread="1"/>
                    <measurement group_id="O2" value="195" spread="1"/>
                    <measurement group_id="O3" value="196" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245" spread="1.1"/>
                    <measurement group_id="O2" value="216" spread="1"/>
                    <measurement group_id="O3" value="215" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated PTH</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting/diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="36"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Low albumin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated phosphorus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="36"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Elevated calcium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Elevated potassium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Elevated white blood count</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ishir Bhan</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-3934</phone>
      <email>ibhan@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

